https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-12-09 17:27:552023-06-14 16:13:40ImaginAb Initiates Phase II Clinical Trial at Penn Medicine
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-12-09 17:27:552023-06-14 16:13:40ImaginAb Initiates Phase II Clinical Trial at Penn Medicine
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-12-05 09:44:532023-06-14 16:14:04Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-12-02 11:46:512023-06-14 16:13:35IXICO to Present Abstracts at Upcoming Clinical Trials on Alzheimer’s Disease Congress
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-12-02 11:31:422023-06-14 16:07:49Owkin Teams up with NVIDIA and King’s College London to Deliver AI to Hospitals While Protecting Patient Data With Federated Learning
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-28 09:27:082023-06-14 16:07:55European CNS Specialist Neuraxpharm Expands Southern European Presence with Expansion into Portugal
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-26 12:34:392023-06-14 16:08:04Novo Seeds expands company formation activities at BiOrigin with seasoned entrepreneurs
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-22 12:28:442023-06-14 16:14:34IXICO Notice of Results
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-21 12:20:232023-06-14 16:13:58Azeria Therapeutics announces £32.0 million series B financing
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-18 12:18:592023-06-14 16:13:52Castor Establishes Advisory Board of Industry Leaders to Maximize the Impact of its Clinical Data Platform
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-14 12:28:352023-06-14 16:13:45Theragnostics strengthens leadership team with two key appointments
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-14 12:16:172023-06-14 16:08:09Calliditas Interim Report Q3, 2019
https://www.optimumcomms.com/wp-content/uploads/2019/11/F2G_Logo_300x180px-80x80-1.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-11 17:49:142023-10-12 11:11:39F2G Receives US FDA Breakthrough Therapy Designation for Olorofim
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-06 09:26:182023-06-14 16:08:25Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-11-05 17:44:162023-06-14 16:08:17IXICO to Present Abstracts at Upcoming Huntington’s Disease and Ataxia Conferences
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-29 10:52:312023-06-14 16:13:28Neuraxpharm enters booming CBD market with the acquisition of leading Switzerland-based S.T.U GMBH
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2019-10-28 09:18:332023-06-14 16:13:25IXICO announces client contracts and appointment of Chief Business OfficerWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
